J INTERN MED:结肠直肠癌家族史与患者生存率

2020-02-09 xing.T MedSci原创

由此可见,该研究的结果表明,有CRC家族史的年轻人可能具有更高的健康意识,参加机会性筛查并改变生活方式,从而获得早期诊断和更好的预后。

大肠癌家族史(CRC)是CRC已知的危险因素,而家族史对患者预后的影响尚不清楚。近日,内科学领域权威杂志Journal of Internal Medicine上发表一篇研究文章,该研究旨在评估了家族史与患者预后之间的关联,并基于当前证据,探讨这种关联是否随诊断时年龄而改变。

研究人员使用的瑞典直肠癌注册中心(SCRCR)的数据,确定了31801名在2007年至2016年期间被诊断为CRC的患者。SCRCR是一个临床资料丰富的数据库,其中包含有关癌症分期、等级的信息、位置、治疗、并发症和术后随访数据。

研究人员使用灵活的参数模型估计了相对存活率的死亡率比(EMRR)和无病生存的风险比(HR)和95%置信区间(CI)。研究人员发现家族史和相对存活率(EMRR=0.96,95%CIs:0.89-1.03,p=0.21)或无病存活率(HR=0.98,95%CIs:0.91-1.06,p=0.64)之间没有关联。然而,研究人员发现年龄改变了家族史对患者预后的影响。有家族史的年轻患者(诊断时<50岁)发生晚期(即I和II期)癌症比没有家族史的年轻患者要少(OR=0.71,95%CI:0.56-0.89,p=0.004),即使调整了癌症分期后,死亡率也有所降低(EMMR=0.63,95%CIs:0.47-0.84,p=0.002)。

由此可见,该研究的结果表明,有CRC家族史的年轻人可能具有更高的健康意识,参加机会性筛查并改变生活方式,从而获得早期诊断和更好的预后。

原始出处:

Francesca Pesola,et al.Family history of colorectal cancer and survival: A Swedish population‐based study.J INTERN MED. 2020.https://onlinelibrary.wiley.com/doi/10.1111/joim.13036

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1932667, encodeId=10d9193266e88, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Jun 01 12:46:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256748, encodeId=e75f1256e4815, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Feb 11 05:46:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479810, encodeId=c2cc14e981079, content=<a href='/topic/show?id=fe7e4641ed7' target=_blank style='color:#2F92EE;'>#家族史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46417, encryptionId=fe7e4641ed7, topicName=家族史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f367584357, createdName=396094184_42047357, createdTime=Tue Feb 11 05:46:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586949, encodeId=77f71586949ca, content=<a href='/topic/show?id=a8fae87846b' target=_blank style='color:#2F92EE;'>#结肠直肠癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78784, encryptionId=a8fae87846b, topicName=结肠直肠癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87c517396713, createdName=lmm403, createdTime=Tue Feb 11 05:46:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610232, encodeId=2583161023286, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Feb 11 05:46:00 CST 2020, time=2020-02-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1932667, encodeId=10d9193266e88, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Jun 01 12:46:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256748, encodeId=e75f1256e4815, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Feb 11 05:46:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479810, encodeId=c2cc14e981079, content=<a href='/topic/show?id=fe7e4641ed7' target=_blank style='color:#2F92EE;'>#家族史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46417, encryptionId=fe7e4641ed7, topicName=家族史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f367584357, createdName=396094184_42047357, createdTime=Tue Feb 11 05:46:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586949, encodeId=77f71586949ca, content=<a href='/topic/show?id=a8fae87846b' target=_blank style='color:#2F92EE;'>#结肠直肠癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78784, encryptionId=a8fae87846b, topicName=结肠直肠癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87c517396713, createdName=lmm403, createdTime=Tue Feb 11 05:46:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610232, encodeId=2583161023286, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Feb 11 05:46:00 CST 2020, time=2020-02-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1932667, encodeId=10d9193266e88, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Jun 01 12:46:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256748, encodeId=e75f1256e4815, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Feb 11 05:46:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479810, encodeId=c2cc14e981079, content=<a href='/topic/show?id=fe7e4641ed7' target=_blank style='color:#2F92EE;'>#家族史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46417, encryptionId=fe7e4641ed7, topicName=家族史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f367584357, createdName=396094184_42047357, createdTime=Tue Feb 11 05:46:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586949, encodeId=77f71586949ca, content=<a href='/topic/show?id=a8fae87846b' target=_blank style='color:#2F92EE;'>#结肠直肠癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78784, encryptionId=a8fae87846b, topicName=结肠直肠癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87c517396713, createdName=lmm403, createdTime=Tue Feb 11 05:46:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610232, encodeId=2583161023286, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Feb 11 05:46:00 CST 2020, time=2020-02-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1932667, encodeId=10d9193266e88, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Jun 01 12:46:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256748, encodeId=e75f1256e4815, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Feb 11 05:46:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479810, encodeId=c2cc14e981079, content=<a href='/topic/show?id=fe7e4641ed7' target=_blank style='color:#2F92EE;'>#家族史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46417, encryptionId=fe7e4641ed7, topicName=家族史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f367584357, createdName=396094184_42047357, createdTime=Tue Feb 11 05:46:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586949, encodeId=77f71586949ca, content=<a href='/topic/show?id=a8fae87846b' target=_blank style='color:#2F92EE;'>#结肠直肠癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78784, encryptionId=a8fae87846b, topicName=结肠直肠癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87c517396713, createdName=lmm403, createdTime=Tue Feb 11 05:46:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610232, encodeId=2583161023286, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Feb 11 05:46:00 CST 2020, time=2020-02-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1932667, encodeId=10d9193266e88, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Jun 01 12:46:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256748, encodeId=e75f1256e4815, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Feb 11 05:46:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479810, encodeId=c2cc14e981079, content=<a href='/topic/show?id=fe7e4641ed7' target=_blank style='color:#2F92EE;'>#家族史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46417, encryptionId=fe7e4641ed7, topicName=家族史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f367584357, createdName=396094184_42047357, createdTime=Tue Feb 11 05:46:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586949, encodeId=77f71586949ca, content=<a href='/topic/show?id=a8fae87846b' target=_blank style='color:#2F92EE;'>#结肠直肠癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78784, encryptionId=a8fae87846b, topicName=结肠直肠癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87c517396713, createdName=lmm403, createdTime=Tue Feb 11 05:46:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610232, encodeId=2583161023286, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Feb 11 05:46:00 CST 2020, time=2020-02-11, status=1, ipAttribution=)]

相关资讯

Cell Death Dis:RNF183通过激活NF-κB-IL-8促进结肠直肠癌细胞的增殖和转移

结肠直肠癌(CRC)是世界上最常见的恶性肿瘤之一,是一种异质性疾病,其发病的主要危险因素包括炎症、家族史、遗传突变及表观遗传学等。既往研究发现环指结构域蛋白涉及致癌作用,而其在CRC中的作用却很少研究。本研究中,研究人员使用公认的GEO数据库的芯片数据重新分析了202个RNF家族成员的表达,发现RNF183在肿瘤组织中明显上调。RNF183高表达与肿瘤大小(P = 0.012),肿瘤浸润深度(P

Brit J Cancer:中国成人肥胖与结肠直肠癌和小肠癌的风险!

由此可见,在相对精瘦的中国成年人中,肥胖与结肠癌和直肠癌的风险相关,男性比女性相关性更密切。

Brit J Cancer:粪便免疫化学检查对结肠直肠癌非警报症状患者的价值

由此可见,在一般临床实践中,FIT检查可以用作表现为CRC非警报症状的CRC和其他严重肠病的诊断过程中的辅助诊断检查。

Mol Ther Nucleic Acids:HOTAIR或是晚期结肠直肠癌新的治疗靶标

晚期结肠直肠癌(CRC)治疗失败的一个主要原因是基于氟化嘧啶(FU)化疗的耐药性的出现。长链非编码RNA HOTAIR已被认为是多种癌症的致癌基因。然而,HOTAIR在化学耐药性中的确切功能机制尚不清楚。在本研究中,研究人员调查了HOTAIR在CRC的5FU耐药性中的生物学和临床作用。结果显示,HOTAIR通过EZH2靶向miR-218-2启动子调节轴负责调控CRC中的miR-218表达。敲低HO

Inter J Cancer:2型糖尿病和结直肠癌存活率的新发现

“国际癌症杂志”发表的一项研究调查了患有或不患有2型糖尿病的结直肠癌患者和其他疾病,如心脏病或中风的存活率。研究结果显示单纯2型糖尿病对结直肠癌患者的生存没有显著影响。然而,2型糖尿病患者以及其他慢性病患者的生存率较低。

Gut:酸奶,为什么只降低男性患肠癌的风险?!

相信大家肯定对酸奶不陌生,就算吃的不多,广告看的肯定不少。酸奶,确实是一种健康食品,适量的摄入可能会改变体内肠道细菌的类型和体积,从而促进肠道健康发育,降低患肠癌的风险。换句人话说,吃酸奶有益肠道健康哦!